Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct-Nov;23(4):132-41.

2015 Update of the Drug Resistance Mutations in HIV-1

Annemarie M Wensing  1 , Vincent Calvez  2 , Huldrych F Günthard  3 , Victoria A Johnson  4 , Roger Paredes  5 , Deenan Pillay  6 , Robert W Shafer  7 , Douglas D Richman  8
Affiliations

2015 Update of the Drug Resistance Mutations in HIV-1

Annemarie M Wensing et al. Top Antivir Med. 2015 Oct-Nov.

Abstract

The 2015 edition of the IAS-USA drug resistance mutations list updates the figures last published in July 2014. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.

PubMed Disclaimer

Conflict of interest statement

Financial affiliations in the past 12 months: The authors (listed alphabetically) disclose the following affiliations with commercial organizations that may have interests related to the content of this article: Dr Calvez has served as an advisor or consultant to and has received research grants from Bristol-Myers Squibb, Gilead Sciences, Inc, Johnson and Johnson, and ViiV Healthcare. Dr Günthard has served on a data and safety monitoring board for Merck & Co, Inc, and has received grants for travel from Gilead Sciences, Inc, and Janssen Therapeutics. Dr Johnson has no relevant financial affiliations to disclose. Dr Paredes has served as a consultant or advisor to Gilead Sciences, Inc, and ViiV Healthcare and has recieved research grants from ViiV Healthcare. Dr Pillay has no relevant financial affiliations to disclose. Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gilead Sciences, Inc, Hera Therapeutics, and Monogram Biosciences, Inc. Dr Shafer has served as a consultant or advisor for Celera and has received grants from Bristol-Myers Squibb, Celera, Gilead Sciences, Inc, Merck & Co, Inc, Roche Molecular, and Siemans Health Care. Dr Wensing has served on advisory boards for Bristol-Myers Squib, Gilead Sciences, Inc, and ViiV Healthcare; has received grants from Janssen Pharmaceuticals, Inc, and Gilead Sciences, Inc; and has received travel, accommodation, or meeting expenses from Gilead Sciences, Inc, and Virology Education.

References

    1. Wensing AM, Calvez V, Günthard HF, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22(3):642-650. - PMC - PubMed
    1. Margot NA, Hluhanich RM, Jones GS, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2012;93(2):288-296. - PubMed
    1. Brenner BG, Lowe M, Moisi D, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011;83(5):751-759. - PubMed
    1. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, noninferiority SAILING study. Lancet. 2013;382(9893):700-708. - PubMed
    1. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86(5):2696-2705. - PMC - PubMed

Publication types

Substances

LinkOut - more resources